Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Eur Rev Med Pharmacol Sci ; 28(5): 1998-2004, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38497882

ABSTRACT

OBJECTIVE: In recent years, an overwhelming association between Pediatric Type 1 Diabetes Mellitus (T1DM) and autoimmune diseases has been largely reported. The current study was designed to determine a possible association between autoimmune thyroiditis (AIT), celiac disease (CD) - associated autoantibodies, and Parvovirus B19 infection among pediatric T1DM cases in the southwestern region of Saudi Arabia. PATIENTS AND METHODS: Blood samples from age groups 1-18 years attending the Diabetic Clinic were collected over a period of 12 months. Serum anti-thyroid peroxidase (TPO), anti-thyroglobulin (TG), anti-tissue transglutaminase immunoglobulin A (TG-IgA), endomysial IgA (EMA-IgA), Parvovirus B19-IgG and IgM antibodies were detected by standard methods. RESULTS: The results showed the prevalence of autoantibodies against thyroid and CD among pediatric T1DM patients to be 44 (25%) and 25 (14.4%), respectively. The prevalence of antibodies against B19 was 70 (40%). Further determination of the prevalence of Parvovirus B19-IgG antibodies and thyroid antibodies among T1DM pediatric patients revealed that there was a significant association between them with a p<0.0491. CONCLUSIONS: The prevalence of autoantibodies against the thyroid was higher among the seropositive Parvovirus B19 children with T1DM. A positive association between the prevalence of autoantibodies against thyroid disease and the increase in the duration of diabetes was also noted. Hence, periodic screening of T1DM patients for B19 antibodies and autoantibodies for thyroid is crucial.


Subject(s)
Celiac Disease , Diabetes Mellitus, Type 1 , Parvovirus B19, Human , Humans , Child , Infant , Child, Preschool , Adolescent , Thyroid Gland , Autoantibodies , Antibodies, Viral , Immunoglobulin G , Celiac Disease/epidemiology , Immunoglobulin A
2.
J Physiol Pharmacol ; 74(5)2023 Oct.
Article in English | MEDLINE | ID: mdl-38085521

ABSTRACT

Clove plant (Syzygium aromaticum) is one of the Myrtaceae family. It's a common flavor in food and the traditional medicine. The study's objective was to ascertain whether the clove bud aqueous extract (CAE) and CAE + nanosilver have any biological effects on immune cells and HT-29 colon cancer cell line. Nanosilver was produced through green synthesis approach using CAE. Produced nanosilver was characterized via electron microscope (scanning, SEM) and ultraviolet-visible spectroscopy. CAE and CAE + nanosilver were examined for their active biomolecules using FTIR analysis, p53 contents using real-time PCR, apoptosis and cell cycle arrest power on HT-29 cancer cell line via flow cytometerty and immunomodulatory potential utilizing MTT assay. Results cleared that a spherical nanosilver with a diameter range of 53 nm was formed by CAE. There were several active biomolecules in CAE and CAE + nanosilver. CAE and CAE + nanosilver increased the p53 protein expression and apoptotic cell number in HT-29 colon cancer cells. CAE and CAE + nanosilver could arrest HT-29 cells at the phase G2/M. CAE and CAE + nanosilver stimulated quiescent and PHA-pre-treated splenic cells at higher concentrations, and CAE suppressed quiescent splenic cell when diluted. In conclusion, the safe edible Syzygium aromaticum plant can be utilized to make anti-tumor agent, essentially for colon tumor. As Syzygium aromaticum plant could stimulate immune cells, it can be used as immune-stimulatory agent that can help fight tumor and tumor development.


Subject(s)
Colonic Neoplasms , Metal Nanoparticles , Syzygium , Humans , Silver/pharmacology , Silver/chemistry , Syzygium/chemistry , Tumor Suppressor Protein p53 , Plant Extracts/pharmacology , Plant Extracts/chemistry
3.
Am J Transplant ; 10(9): 1970-80, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20883532

ABSTRACT

B cells are recognized as effector cells in allograft rejection that are dependent upon T cell help to produce alloantibodies causing graft injury. It is not known if B cells can also help T cells differentiate into memory cells in the alloimmune response. We found that in B-cell-deficient hosts, differentiation of alloreactive T cells into effectors was intact whereas their development into memory T cells was impaired. To test if B cell help for T cells was required for their continued differentiation into memory T cells, activated T cells were sorted from alloimmunized mice and transferred either with or without B cells into naïve adoptive hosts. Activated T cells cotransferred with B cells gave rise to more memory T cells than those transferred without B cells and upon recall, mediated accelerated rejection of skin allografts. Cotransfer of B cells led to increased memory T cells by enhancing activated CD4 T-cell proliferation and activated CD8 T-cell survival. These results indicate that B cells help alloreactive T-cell differentiation, proliferation and survival to generate optimal numbers of functional memory T cells.


Subject(s)
B-Lymphocytes/physiology , Cell Differentiation , Immunologic Memory , T-Lymphocytes/cytology , T-Lymphocytes/immunology , Adoptive Transfer , Animals , B-Lymphocytes/cytology , B-Lymphocytes/transplantation , CD4-Positive T-Lymphocytes/cytology , CD8-Positive T-Lymphocytes/cytology , Cell Count , Cell Differentiation/immunology , Cell Proliferation , Cell Survival/physiology , Graft Rejection/etiology , Graft Rejection/pathology , Immunologic Memory/physiology , Isoantibodies/blood , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Skin Transplantation , T-Lymphocytes/transplantation , Time Factors , Transplantation, Homologous
4.
Physiol Int ; 103(4): 469-480, 2016 Dec.
Article in English | MEDLINE | ID: mdl-28229630

ABSTRACT

Background Type 2 diabetes mellitus (T2DM)-induced neuropathy and ischemia-reperfusion post-surgery prolong carpal tunnel syndrome (CTS) pathology, but the effect of T2DM on the prognostic outcome of carpal tunnel (CT) release surgery needs to be investigated. Materials and methods A total of 64 individuals with CTS underwent CT release surgery. HbA1c levels identified their diabetic status. The individual prognostic outcomes were measured by nerve conduction velocity (NCV), amplitude, and latency. Measurement of [Ca2+]c and reactive oxygen species (ROS) from isolated endothelial cells (ECs) revealed the oxidative burden of the normal and diabetic CTS phenotypes. Results CTS individuals with HbA1c > 7 showed decreased NCV (≈22 m/s) and amplitude (≈4.2 mV) with increased latency (≈6 ms), compared to groups with HbA1c ≤ 7. Further to CT release surgery, the reversal of the nerve conduction to normalcy was greatly influenced by the diabetic profile of the individuals. Our results showed elevated basal [Ca2+]c and corresponding high cytosolic ROS in the ECs isolated from individuals with HbA1c > 7 compared to the diabetic and healthy control groups. Conclusion The individuals with diabetic index showed suboptimal neuronal performance pre- and post-CT release surgery. Oxidative stress mediated by high [Ca2+]c and ROS of ECs dissipates to adjoining cells worsening the pathology of the untreated CTS.


Subject(s)
Calcium/metabolism , Carpal Tunnel Syndrome/surgery , Cytosol/metabolism , Diabetes Mellitus, Type 2/complications , Diabetic Neuropathies/surgery , Endothelial Cells/metabolism , Orthopedic Procedures , Adult , Biomarkers/blood , Carpal Tunnel Syndrome/etiology , Carpal Tunnel Syndrome/metabolism , Carpal Tunnel Syndrome/physiopathology , Cells, Cultured , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/therapy , Diabetic Neuropathies/etiology , Diabetic Neuropathies/metabolism , Diabetic Neuropathies/physiopathology , Female , Glycated Hemoglobin/metabolism , Humans , Male , Middle Aged , Neural Conduction , Orthopedic Procedures/adverse effects , Oxidative Stress , Postoperative Complications/etiology , Postoperative Complications/metabolism , Postoperative Complications/physiopathology , Reaction Time , Reactive Oxygen Species/metabolism , Recovery of Function , Time Factors , Treatment Outcome , Up-Regulation
SELECTION OF CITATIONS
SEARCH DETAIL